Want to see NAUT full AI Analyst Report?
Top Page
Nautilus Biotechnolgy
(NASDAQ:NAUT)
Select Model
Select Model
Rating:46Neutral
Price Target:
$0.88
▼(-47.81% Downside)
Action:Reiterated
Date:07/30/26
The score is held down primarily by weak financial performance (minimal revenue, large losses, and significant negative free cash flow) and bearish technical positioning (trading below all major moving averages). The earnings call provides a partial offset via clear commercialization milestones, improved cost control, and stated liquidity/runway, but near-term revenue remains limited and execution/timing risks are still meaningful.
Positive Factors
Unique scientific differentiation (proteoform insights)
Nautilus's ability to generate proteoform‑level discoveries (e.g., distinctive Tau distributions) represents a durable scientific moat. Proprietary single‑molecule data can drive high‑value collaborations, publications, and training datasets for AI, supporting long‑term demand from biopharma and research customers.
Negative Factors
Minimal revenue and pre‑commercial status
Revenue remains negligible, reflecting a pre‑commercial business model. With almost no recurring sales, the company must convert instrument/service proofs into sustained customer revenue; failure to do so would prevent scale, hinder margin improvement, and keep the business reliant on financing.
Read all positive and negative factors
Positive Factors
Negative Factors
Unique scientific differentiation (proteoform insights)
Nautilus's ability to generate proteoform‑level discoveries (e.g., distinctive Tau distributions) represents a durable scientific moat. Proprietary single‑molecule data can drive high‑value collaborations, publications, and training datasets for AI, supporting long‑term demand from biopharma and research customers.
Read all positive factors
Nautilus Biotechnolgy (NAUT) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$124.33M
Dividend YieldN/A
Average Volume (3M)975.43K
Price to Earnings (P/E)―
Beta (1Y)1.32
Revenue GrowthN/A
EPS Growth14.45%
CountryUS
Employees130
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-0.45
Shares Outstanding127,255,226
10 Day Avg. Volume548,452
30 Day Avg. Volume975,432
Financial Highlights & Ratios
PEG Ratio0.26
Price to Book (P/B)1.57
Price to Sales (P/S)0.00
P/FCF Ratio-4.74
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit>-0.01
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price Target
$4.00Price Target Upside136.69% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
EPS Forecast (FY)-0.52
Revenue Forecast (FY)$700.00K
Nautilus Biotechnolgy Business Overview & Revenue Model
Company Description
Nautilus Biotechnology, Inc., a development stage life sciences company, engages in creating a platform technology for quantifying and unlocking the complexity of the proteome in the United States. The company develops Nautilus Voyager Platform, w...
How the Company Makes Money
null...
Nautilus Biotechnolgy Earnings Call Summary
Earnings Call Date:Apr 28, 2026
(Q1-2026)
| % Change Since: |
Next Earnings Date:Nov 03, 2026
Earnings Call Sentiment Positive
The call emphasized substantive technical and commercial progress: verified service lab, strong scientific collaborator results (including novel ApoE–Tau proteoform findings), nearly tripled qualified probes, targeted oncology assay progress, and deliberate commercial hires. Financially the company reduced operating expenses YoY and exited the quarter with $143.4M in cash and a stated runway through 2027. Offsetting these positives are external delays (Middle East conflict) that pushed grant revenue recognition and some reagent development later in the year, a nascent sales pipeline with only one named EAP customer so far, remaining verification/validation work before broadscale customer deployments, and modest expected revenue (~$0.5M) for 2026. On balance, accomplishments materially outweigh the challenges but execution and timing risks remain.Positive Updates
Early Access Program Launch and Strategic Collaborations
Launched Iterative Mapping Early Access Program in January 2026 and debuted the Voyager platform at US HUPO; established collaborations including the Michael J. Fox Foundation/Weill Cornell Medicine-Qatar alpha-synuclein program and ongoing work with Buck Institute and Allen Institute, enabling unique proteoform-level biological insights.
Negative Updates
Revenue and Grant Recognition Delays
Revenue recognition tied to the Michael J. Fox Foundation grant progressed more slowly than anticipated due to delays related to the ongoing conflict in the Middle East; company now expects approximately $0.5M in total revenue for the year with a greater portion shifting into later quarters.
Read all updates
Q1-2026 Updates
Positive
Negative
Early Access Program Launch and Strategic Collaborations
Launched Iterative Mapping Early Access Program in January 2026 and debuted the Voyager platform at US HUPO; established collaborations including the Michael J. Fox Foundation/Weill Cornell Medicine-Qatar alpha-synuclein program and ongoing work with Buck Institute and Allen Institute, enabling unique proteoform-level biological insights.
Read all positive updates
Company Guidance
Nautilus reiterated a detailed commercialization timetable and metric-backed progress: it plans to expand Iterative Mapping Early Access in H2 2026 with a second (oncology) proteoform assay, introduce broadscale capabilities into early access later in 2026, begin beta Voyager placements in late Q3/Q4 2026, open preorders in late 2026 with customer installations starting in early 2027 and general availability of broadscale capabilities in H1 2027. Operationally, the company has one named EAP customer (Baylor College of Medicine), active collaborations with the Buck Institute, Allen Institute and Neural Stem Cell Institute, an Alpha instrument in the field for ~1 year, a sales team of three (VP Amber Faust +2 hires), a service lab that passed verification/validation (meeting accuracy, dynamic range, reproducibility and stability requirements), nearly tripled the number of probes qualified as assay-compatible this quarter and completed its largest number of high‑cycle decode experiments while routinely testing lysate mixtures and full lysates. Financially, Q1 operating expenses were $16.1M (R&D $9.7M, down 16% Y/Y; G&A $6.4M, down 12% Y/Y), Q1 cash burn was $12.8M (including $1.1M from option exercises), cash and investments were $143.4M at quarter end, management expects roughly $0.5M revenue for the year (shifted into later quarters) and believes the cash runway extends through 2027.Nautilus Biotechnolgy Financial Statement Overview
Summary
Income Statement
18
Very Negative
Balance Sheet
56
Neutral
Cash Flow
22
Negative
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 190.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | -1.75M | -6.46M | -6.35M | -5.71M | 0.00 | -2.84M |
| EBITDA | -55.02M | -52.54M | -64.43M | -61.83M | -60.08M | -47.47M |
| Net Income | -56.52M | -59.00M | -70.78M | -63.67M | -57.92M | -50.31M |
Balance Sheet | ||||||
| Total Assets | 163.58M | 191.11M | 242.74M | 305.56M | 350.05M | 398.45M |
| Cash, Cash Equivalents and Short-Term Investments | 84.03M | 103.41M | 129.89M | 173.42M | 184.47M | 345.73M |
| Total Debt | 27.82M | 30.02M | 30.48M | 34.63M | 30.33M | 30.03M |
| Total Liabilities | 32.46M | 34.14M | 34.01M | 40.21M | 35.13M | 34.87M |
| Stockholders Equity | 131.11M | 156.97M | 208.73M | 265.35M | 314.92M | 363.58M |
Cash Flow | ||||||
| Free Cash Flow | -51.86M | -51.97M | -61.27M | -54.15M | -48.13M | -41.51M |
| Operating Cash Flow | -50.23M | -50.70M | -59.15M | -51.71M | -45.81M | -39.24M |
| Investing Cash Flow | 27.49M | 35.22M | 66.25M | -43.73M | -25.74M | -138.96M |
| Financing Cash Flow | 1.45M | 214.00K | 1.14M | 368.00K | 562.00K | 327.45M |
Nautilus Biotechnolgy Risk Analysis
Nautilus Biotechnolgy disclosed 68 risk factors in its most recent earnings report. Nautilus Biotechnolgy reported the most risks in the "Finance & Corporate" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Nautilus Biotechnolgy Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
51 Neutral | $122.80M | -1.79 | -26.58% | ― | -1.44% | 11.50% | |
46 Neutral | $124.33M | -2.17 | -37.58% | ― | ― | 14.45% | |
46 Neutral | $155.29M | -1.15 | -123.07% | ― | ― | 3.91% | |
44 Neutral | $76.61M | -1.63 | -72.78% | ― | ― | 73.91% | |
42 Neutral | $9.89M | -0.13 | -133.02% | ― | ― | ― |
* Healthcare Sector Average
NAUT
Nautilus Biotechnolgy
0.90
0.17
23.29%
VTGN
VistaGen Therapeutics
0.29
-2.68
-90.34%
KLRS
Kalaris Therapeutics
4.07
1.40
52.43%
SEER
Seer
2.17
-0.13
-5.65%
ABOS
Acumen Pharmaceuticals
2.44
1.08
79.41%
Nautilus Biotechnolgy Corporate Events
Executive/Board ChangesShareholder Meetings
Nautilus Biotech stockholders approve directors and governance items
Positive
Jun 18, 2026
Nautilus Biotechnology, Inc. held its 2026 annual meeting of stockholders on June 17, 2026, with 85,002,191 of 127,078,855 eligible shares represented, and stockholders elected Parag Mallick and Farzad Nazem as Class II directors to serve until th...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.